WO2017221215A1 - Salts of lenvatinib - Google Patents
Salts of lenvatinib Download PDFInfo
- Publication number
- WO2017221215A1 WO2017221215A1 PCT/IB2017/053777 IB2017053777W WO2017221215A1 WO 2017221215 A1 WO2017221215 A1 WO 2017221215A1 IB 2017053777 W IB2017053777 W IB 2017053777W WO 2017221215 A1 WO2017221215 A1 WO 2017221215A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lenvatinib
- crystalline
- crystalline form
- xrpd pattern
- values
- Prior art date
Links
- WOSKHXYHFSIKNG-UHFFFAOYSA-N COc1cc2nccc(Oc(cc3Cl)ccc3NC(NC3CC3)=O)c2cc1C(N)=O Chemical compound COc1cc2nccc(Oc(cc3Cl)ccc3NC(NC3CC3)=O)c2cc1C(N)=O WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the present invention provides salts of lenvatinib, particularly, lenvatinib acetate, lenvatinib L-proline, lenvatinib maleate, lenvatinib citrate, lenvatinib salicylate, lenvatinib succinate, lenvatinib L-pyroglutamate, their polymorphic forms, processes for their preparation, and pharmaceutical compositions thereof.
- the present invention further relates to the use of these salts of lenvatinib for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
- Lenvatinib mesylate of Formula A is chemically known as 4-[3-chloro-4-(N'- cyclopropylureido)phenoxy] -7-methoxyquinoline-6-carboxamide methanesulfonate .
- Lenvatinib mesylate is a kinase inhibitor, indicated for the treatment of differentiated thyroid cancer (DTC) as a single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC and for the treatment of renal cell cancer (RCC) in combination with everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy.
- DTC differentiated thyroid cancer
- RCC renal cell cancer
- U.S. Patent No. 7,253,286 provides a process for the preparation of lenvatinib.
- U.S. Patent No. 7,612,208 provides processes for the preparation of crystalline lenvatinib hydrochloride, crystalline lenvatinib hydrobromide, crystalline lenvatinib tosylate, crystalline lenvatinib sulfate, crystalline lenvatinib methanesulfonate Form A, crystalline lenvatinib methanesulfonate Form B, crystalline lenvatinib methanesulfonate Form C, crystalline lenvatinib methanesulfonate acetic acid solvate Form I, crystalline lenvatinib methanesulfonate hydrate Form F, crystalline lenvatinib methanesulfonate dimethylsulfoxide solvate, crystalline lenvatinib ethane sulfonate Form a, crystalline lenvatinib ethanesulfonate Form ⁇ , and crystalline lenvatinib e
- the present invention provides a compound of Formula 1
- HX is selected from the group consisting of acetic acid, L-proline, maleic acid, citric acid, salicylic acid, succinic acid, and L-pyroglutamic acid and processes for their preparation.
- the present invention provides lenvatinib acetate, lenvatinib L- proline, lenvatinib maleate, lenvatinib citrate, lenvatinib salicylate, lenvatinib succinate, lenvatinib L-pyroglutamate, their polymorphic forms, processes for their preparation, and pharmaceutical compositions thereof.
- the present invention further relates to the use of these salts of lenvatinib for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
- Figure 1 depicts an X-Ray Powder Diffraction (XRPD) pattern of crystalline lenvatinib acetate prepared as per Example 1.
- Figure 2 depicts a Differential Scanning Calorimetry (DSC) thermogram of crystalline lenvatinib acetate prepared as per Example 1.
- Figure 3 depicts the Fourier-Transform Infrared ( ⁇ ) spectrum of crystalline lenvatinib acetate prepared as per Example 1.
- Figure 4 depicts an XRPD pattern of crystalline lenvatinib L-proline prepared as per Example 2.
- Figure 5 depicts a DSC thermogram of crystalline lenvatinib L-proline prepared as per Example 2.
- Figure 6 depicts the FTIR spectrum of crystalline lenvatinib L-proline prepared as per Example 2.
- Figure 7 depicts an XRPD pattern of crystalline lenvatinib maleate prepared as per Example 3.
- Figure 8 depicts a DSC thermogram of crystalline lenvatinib maleate prepared as per Example 3.
- Figure 9 depicts the FTIR spectrum of crystalline lenvatinib maleate prepared as per Example 3.
- Figure 10 depicts an XRPD pattern of crystalline lenvatinib citrate prepared as per
- Figure 1 1 depicts a DSC thermogram of crystalline lenvatinib citrate prepared as per Example 4.
- Figure 12 depicts the FTIR spectrum of crystalline lenvatinib citrate prepared as per Example 4.
- Figure 13 depicts an XRPD pattern of crystalline lenvatinib salicylate prepared as per Example 5.
- Figure 14 depicts a DSC thermogram of crystalline lenvatinib salicylate prepared as per Example 5.
- Figure 15 depicts the FTIR spectrum of crystalline lenvatinib salicylate prepared as per Example 5.
- Figure 16 depicts an XRPD pattern of crystalline lenvatinib succinate prepared as per Example 6.
- Figure 17 depicts a DSC thermogram of crystalline lenvatinib succinate prepared as per Example 6.
- Figure 18 depicts the FTIR spectrum of crystalline lenvatinib succinate prepared as per Example 6.
- Figure 19 depicts an XRPD pattern of crystalline lenvatinib L-pyroglutamate prepared as per Example 7.
- Figure 20 depicts a DSC thermogram of crystalline lenvatinib L-pyroglutamate prepared as per Example 7.
- Figure 21 depicts the FTIR spectrum of crystalline lenvatinib L-pyroglutamate prepared as per Example 7.
- solvent includes single solvents or solvent mixtures, such as water, esters, alkanols, halogenated hydrocarbons, ketones, ethers, polar aprotic solvents, or mixtures thereof.
- esters include ethyl acetate, n-propyl acetate, isopropyl acetate, and n-butyl acetate.
- alkanols include those primary, secondary, and tertiary alcohols having from one to six carbon atoms.
- alkanols include methanol, ethanol, n-propanol, isopropanol, butanol, 2-methoxyethanol, and 2-ethoxyethanol.
- halogenated hydrocarbons include dichloromethane, chloroform, and 1,2- dichloroethane.
- ketones include acetone and methyl ethyl ketone.
- ethers include diethyl ether and tetrahydrofuran.
- polar aprotic solvents include N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile, and N-methylpyrrolidone.
- a first aspect of the present invention provides a compound of Formula 1
- HX is selected from the group consisting of acetic acid, L-proline, maleic acid, citric acid, salicylic acid, succinic acid, and L-pyroglutamic acid.
- the compound of Formula 1 of the present invention may be in crystalline form or in an amorphous form.
- the present invention provides crystalline lenvatinib acetate.
- Crystalline lenvatinib acetate is characterized by an XRPD pattern having interplanar spacing (d) values at about 21.9, 7.2, 5.4, 4.1, and 3.3 (A).
- Crystalline lenvatinib acetate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 8.6, 6.4, 4.7, 4.6, 3.8, 3.2, and 3.0 (A).
- Crystalline lenvatinib acetate is characterized by an XRPD pattern having characteristic peak values (2 ⁇ ) at about 4.0, 12.3, 16.4, 21.6, 26.6 ⁇ 0.2°. Crystalline lenvatinib acetate is further characterized by an XRPD pattern having additional characteristic peak values (2 ⁇ ) at 10.3, 13.9, 18.9, 19.4, 23.4, 28.0, and 29.4 ⁇ 0.2°.
- Table 1 provides the interplanar spacing (d) values (A), the corresponding peak values (2 ⁇ ), and the relative intensity of crystalline lenvatinib acetate.
- Crystalline lenvatinib acetate is characterized by X-ray powder diffraction (XRPD) pattern substantially as depicted in Figure 1.
- Crystalline lenvatinib acetate is characterized by a Differential Scanning Calorimetry (DSC) thermogram having an endothermic peak value at about 226.58°C.
- DSC Differential Scanning Calorimetry
- Crystalline lenvatinib acetate is characterized by a Fourier-Transform Infrared (FTIR) spectrum as depicted in Figure 3.
- FTIR Fourier-Transform Infrared
- the present invention provides crystalline lenvatinib L-proline.
- Crystalline lenvatinib L-proline is characterized by an XRPD pattern having interplanar spacing (d) values at about 21.9, 7.2, 5.4, 4.7, and 3.4 (A).
- Crystalline lenvatinib L-proline is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 8.6, 4.3, 4.1, 3.8, 3.2, 3.1, and 3.0 (A).
- Crystalline lenvatinib L-proline is characterized by an XRPD pattern having characteristic peak values (2 ⁇ ) at about 4.0, 12.3, 16.4, 18.9, and 26.6 ⁇ 0.2°. Crystalline lenvatinib L-proline is further characterized by an XRPD pattern having additional characteristic peak values (2 ⁇ ) at 10.2, 20.8, 21.6, 23.3, 28.0, 29.0, and 29.3 ⁇ 0.2°.
- Table 2 provides the interplanar spacing (d) values (A), the corresponding peak values (2 ⁇ ), and the relative intensity of crystalline lenvatinib L-proline.
- Crystalline lenvatinib L-proline is characterized by an XRPD pattern as depicted in Figure 4.
- Crystalline lenvatinib L-proline is characterized by a DSC thermogram having an endothermic peak value at about 225.27°C.
- Crystalline lenvatinib L-proline is characterized by a DSC thermogram as depicted in Figure 5.
- Crystalline lenvatinib L-proline is characterized by a FTIR spectrum as depicted in Figure 6.
- the present invention provides crystalline lenvatinib maleate.
- Crystalline lenvatinib maleate is characterized by an XRPD pattern having interplanar spacing (d) values at about 19.7, 9.8, 6.0, 3.9, and 3.4 (A).
- Crystalline lenvatinib maleate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 13.9, 9.2, 8.5, 6.3, 4.1, 3.2, and 3.0 (A).
- Crystalline lenvatinib maleate is characterized by an XRPD pattern having characteristic peak values (2 ⁇ ) at about 4.5, 9.0, 14.6, 22.5, and 26.5 ⁇ 0.2°.
- Crystalline lenvatinib maleate is further characterized by an XRPD pattern having additional characteristic peak values (2 ⁇ ) at 6.4, 9.6, 10.4, 14.1, 21.7, 27.9, 29.4 ⁇ 0.2°.
- Table 3 provides the interplanar spacing (d) values (A), the corresponding peak values (2 ⁇ ), and the relative intensity of crystalline lenvatinib maleate.
- Crystalline lenvatinib maleate is characterized by an XRPD pattern as depicted in Figure 7.
- Crystalline lenvatinib maleate is characterized by a DSC thermogram having endothermic peaks value at about 73.26°C and 172.69°C.
- Crystalline lenvatinib maleate is characterized by a DSC thermogram as depicted in Figure 8.
- Crystalline lenvatinib maleate is characterized by a FTIR spectrum as depicted in Figure 9.
- the present invention provides crystalline lenvatinib citrate.
- Crystalline lenvatinib citrate is characterized by an XRPD pattern having interplanar spacing (d) values at about 7.2, 4.7, 4.1, 3.4, and 3.1 (A).
- Crystalline lenvatinib citrate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 21.9, 8.6, 5.4, 4.3, 3.8, and 3.2 (A).
- Crystalline lenvatinib citrate is characterized by an XRPD pattern having characteristic peak values (2 ⁇ ) at about 12.3, 18.9, 21.6, 26.5, and 29.3 ⁇ 0.2°. Crystalline lenvatinib citrate is further characterized by an XRPD pattern having additional characteristic peak values (2 ⁇ ) at 4.0, 10.2, 16.4, 20.8, 23.3, and 27.9 ⁇ 0.2°.
- Table 4 provides the interplanar spacing (d) values (A), the corresponding peak values (2 ⁇ ), and the relative intensity of crystalline lenvatinib citrate.
- Crystalline lenvatinib citrate is characterized by an XRPD pattern substantially as depicted in Figure 10. Crystalline lenvatinib citrate is characterized by a DSC thermogram having an endothermic peak value at about 227.72°C and an exothermic peak value at about 270.04°C.
- Crystalline lenvatinib citrate is characterized by a DSC thermogram as depicted in Figure 11.
- Crystalline lenvatinib citrate is characterized by a FTIR spectrum as depicted in Figure 12.
- the present invention provides crystalline lenvatinib salicylate.
- Crystalline lenvatinib salicylate is characterized by an XRPD pattern having interplanar spacing (d) values at about 25.3, 8.3, and 5.0 (A).
- Crystalline lenvatinib salicylate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about at 21.9, 7.2, 7.0, 6.0, 5.4, 4.1, 4.0, 3.5, and 3.3 (A).
- Crystalline lenvatinib salicylate is characterized by an XRPD pattern having characteristic peak values (2 ⁇ ) at about 3.5, 10.6, and 17.8 ⁇ 0.2°. Crystalline lenvatinib salicylate is further characterized by an XRPD pattern having additional characteristic peak values (20) at 4.O, 12.3, 12.6, 14.8, 16.4, 21.4, 22.2, 25.2, and 26.8 ⁇ 0.2°.
- Table 5 provides the d-spacing values (A), the corresponding 2 ⁇ values, and the relative intensity of crystalline lenvatinib salicylate.
- Crystalline lenvatinib salicylate is characterized by an XRPD pattern substantially as depicted in Figure 13.
- Crystalline lenvatinib salicylate is characterized by a DSC thermogram having an endothermic peak value at about 214.47°C.
- Crystalline lenvatinib salicylate is characterized by a DSC thermogram as depicted in Figure 14.
- Crystalline lenvatinib salicylate is characterized by a FTIR spectrum as depicted in Figure 15.
- the present invention provides crystalline lenvatinib succinate.
- Crystalline lenvatinib succinate is characterized by an XRPD pattern having interplanar spacing (d) values at about 21.7, 8.6, 7.2, 5.4, 4.1, and 3.3 (A).
- Crystalline lenvatinib succinate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 8.6, 4.7, 4.3, 3.8, 3.2, 3.1, and 3.0 (A).
- Crystalline lenvatinib succinate is characterized by an XRPD pattern having characteristic peak values (2 ⁇ ) at about 4.1, 10.3, 12.3, 16.4, 21.6, and 26.6 ⁇ 0.2°. Crystalline lenvatinib succinate is further characterized by an XRPD pattern having additional characteristic peak values (2 ⁇ ) at 10.3, 18.9, 20.8, 23.3, 28.0, 29.0, and 29.4 ⁇ 0.2°. Table 6 provides the interplanar spacing (d) values (A), the corresponding peak values (2 ⁇ ), and the relative intensity of crystalline lenvatinib succinate.
- Crystalline lenvatinib succinate is characterized by an XRPD pattern substantially as depicted in Figure 16.
- Crystalline lenvatinib succinate is characterized by a DSC thermogram having an endothermic peak value at about 226.17°C and an exothermic peak value at about 268.97°C.
- Crystalline lenvatinib succinate is characterized by a DSC thermogram as depicted in Figure 17.
- Crystalline Form of lenvatinib succinate is characterized by a FTIR spectrum as depicted in Figure 18.
- the present invention provides crystalline lenvatinib L-pyroglutamate.
- Crystalline lenvatinib L-pyroglutamate is characterized by an XRPD pattern having interplanar spacing (d) values at about 21.6, 7.2, 5.4, 4.1, and 3.3 (A).
- Crystalline lenvatinib L-pyroglutamate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about at 8.6, 4.7, 4.0, 3.8, 3.2, 3.1, 3.1, and 3.0 (A).
- Crystalline lenvatinib L-pyroglutamate is characterized by an XRPD pattern having characteristic peak values (2 ⁇ ) at about 4.1, 12.3, 16.5, 21.6, and 26.6 ⁇ 0.2°. Crystalline lenvatinib L-pyroglutamate is further characterized by an XRPD pattern having additional characteristic peak values (2 ⁇ ) at 10.3, 19.0, 21.9, 23.3, 28.0, 28.6, 29.0, and 29.3 ⁇ 0.2°.
- Table 7 provides the interplanar spacing (d) values (A), the corresponding peak values (2 ⁇ ), and the relative intensity of crystalline lenvatinib L-pyroglutamate.
- Crystalline lenvatinib L-pyroglutamate is characterized by an XRPD pattern substantially as depicted in Figure 19.
- Crystalline lenvatinib L-pyroglutamate is characterized by a DSC thermogram having endothermic peak values at about 151.77°C and 199.85°C.
- Crystalline lenvatinib L-pyroglutamate is characterized by a DSC thermogram as depicted in Figure 20.
- Crystalline lenvatinib L-pyroglutamate is characterized by a FTIR spectrum as depicted in Figure 21.
- a second aspect of the present invention provides a process for the preparation of a compound of Formula 1
- HX is selected from the group consisting of acetic acid, L-proline, maleic acid, citric acid, salicylic acid, succinic acid, and L-pyroglutamic acid.
- Lenvatinib free base used as the starting material may be prepared by any methods known in the art including those described in, for example, U.S. Patent Nos. 7,253,286, and 7,683,172.
- Lenvatinib free base prepared by any methods known in the art may be isolated or directly treated with HX.
- Lenvatinib free base prepared by any methods known in the art may be optionally purified prior to treatment with HX to remove foreign particulate matter. Alternatively, it may be treated with activated charcoal in a suitable solvent to remove coloring and other related impurities.
- the treatment of lenvatinib free base with HX includes adding, slurrying, dissolving, stirring, or a combination thereof in the presence of a suitable solvent at a temperature of about 25 °C to reflux temperature for a time period sufficient to complete the reaction.
- the molar ratio of lenvatinib free base to HX may be about 1 :0.5 to about 1 :2, which may be preferably 1 : 1.
- compound of Formula 1 can be isolated by cooling, extraction, washing, crystallization, precipitation, filtration, filtration under vacuum, decantation, centrifugation, drying, or combinations thereof.
- the compound of Formula 1 obtained by the process above is crystalline or amorphous.
- lenvatinib is treated with acetic acid at a temperature of about 25°C to 30°C in methanol to isolate crystalline lenvatinib acetate.
- lenvatinib free base is treated with L-proline at a temperature of about 25°C to 75°C in ethanol to isolate crystalline lenvatinib L- proline.
- lenvatinib free base is treated with maleic acid at a temperature of about 25 °C to 75 °C in ethanol to isolate crystalline lenvatinib maleate.
- lenvatinib free base is treated with citric acid at a temperature of about 25 °C to 65 °C in methanol to isolate crystalline lenvatinib citrate.
- lenvatinib free base is treated with salicylic acid at a temperature of about 25 °C to 65 °C in methanol to isolate crystalline lenvatinib salicylate.
- lenvatinib free base is treated with L- pyroglutamic acid at a temperature of about 25°C to 70°C in ethanol to isolate crystalline lenvatinib L-pyroglutamate.
- a third aspect of the present invention provides the use of compound of Formula 1 for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
- the compound of Formula 1 can be used for the preparation of lenvatinib free base by contacting with a base.
- the base may be selected from the group consisting of hydroxides, carbonates, and bicarbonates of alkali and alkaline earth metals, ammonia, alkyl amines, hydrazine, and the like.
- hydroxides, carbonates, and bicarbonates of alkali and alkaline earth metals include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, and potassium bicarbonate.
- alkyl amines include diethylamine, triethylamine, and methyldiethylamine.
- Lenvatinib free base thus obtained may be converted to salts, solvates, or polymorphs thereof by any of the methods known in the art.
- lenvatinib free base obtained may be converted to the mesylate salt including those described in, for example, U.S. Patent Nos. 7,612,208
- a fourth aspect of the present invention provides a pharmaceutical composition comprising a compound of Formula 1 and a pharmaceutically acceptable carrier.
- Acetic acid (0.14 g) was added to a mixture of lenvatinib free base (1 g) and methanol (15 mL) at 25 °C to 30°C and stirred for 24 hours.
- the solid obtained was filtered and then washed with methanol (2x5 mL). The solid was dried under reduced pressure at 45°C to 50°C for 15 hours to obtain the title compound.
- Citric acid (0.247 g) was added to a mixture of lenvatinib free base (0.5 g) and methanol (10 mL) at 64°C to 65°C and stirred for 1 hour. The reaction mixture was cooled to 25°C to 30°C and stirred for 15 hours. The solid obtained was filtered and then washed with methanol (2x5mL). The solid was dried under reduced pressure at 50°C to 55°C for 18 hours to obtain the title compound.
- Example 5 Preparation of Lenvatinib Salicylate: Salicylic acid (0.18 g) was added to a mixture of lenvatinib free base (0.5 g) and methanol (10 mL) at 64°C to 65°C and stirred for 1 hour. The reaction mixture was cooled to 25 °C to 30°C and then stirred for 15 hours. The solid obtained was filtered and then washed with methanol (2x5mL). The solid was dried under reduced pressure at 50°C to 55°C for 18 hours to obtain the title compound.
- Succinic acid (0.15 g) was added to a mixture of lenvatinib free base (0.5 g) and ethanol (10 mL) at 70°C and stirred for 1 hour at 65-70°C.
- the reaction mixture was cooled to 25 °C to 30°C and then stirred for 15 hours at 25 °C to 30°C.
- the solid obtained was filtered and then washed with ethanol (5mL). The solid was dried under reduced pressure at 50°C to 55°C for 18 hours to obtain the title compound.
- L-pyroglutamic acid (0.18 g) was added to a mixture of lenvatinib free base (0.5 g) and ethyl acetate (20 mL) at 70°C and stirred for 1 hour at 68-70°C.
- the reaction mixture was cooled to 25 °C to 30°C and then stirred for 15 hours.
- the solid obtained was filtered and then washed with ethyl acetate (2x5 mL). The solid was dried under reduced pressure at 50°C to 55°C for 18 hours to obtain the title compound.
- a suspension of compound of Formula 1 in water (about 10 times) is cooled to 10°C and then the pH is adjusted to 8-9 using aqueous ammonia solution.
- the reaction mixture is stirred for 30 minutes, the material is filtered, and dried to obtain the title compound.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides salts of lenvatinib, particularly, lenvatinib acetate, lenvatinib L-proline, lenvatinib maleate, lenvatinib citrate, lenvatinib salicylate, lenvatinib succinate, lenvatinib L-pyroglutamate, their polymorphic forms, processes for their preparation, and pharmaceutical compositions thereof. The present invention further relates to the use of these salts of lenvatinib for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
Description
SALTS OF LENVATINIB
Field of the Invention
The present invention provides salts of lenvatinib, particularly, lenvatinib acetate, lenvatinib L-proline, lenvatinib maleate, lenvatinib citrate, lenvatinib salicylate, lenvatinib succinate, lenvatinib L-pyroglutamate, their polymorphic forms, processes for their preparation, and pharmaceutical compositions thereof. The present invention further relates to the use of these salts of lenvatinib for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
Background of the Invention
Lenvatinib mesylate of Formula A is chemically known as 4-[3-chloro-4-(N'- cyclopropylureido)phenoxy] -7-methoxyquinoline-6-carboxamide methanesulfonate .
Formula A
Lenvatinib mesylate is a kinase inhibitor, indicated for the treatment of differentiated thyroid cancer (DTC) as a single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC and for the treatment of renal cell cancer (RCC) in combination with everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy.
U.S. Patent No. 7,253,286 provides a process for the preparation of lenvatinib.
U.S. Patent No. 7,612,208 provides processes for the preparation of crystalline lenvatinib hydrochloride, crystalline lenvatinib hydrobromide, crystalline lenvatinib tosylate, crystalline lenvatinib sulfate, crystalline lenvatinib methanesulfonate Form A, crystalline lenvatinib methanesulfonate Form B, crystalline lenvatinib methanesulfonate Form C, crystalline lenvatinib methanesulfonate acetic acid solvate Form I, crystalline lenvatinib methanesulfonate hydrate Form F, crystalline lenvatinib methanesulfonate
dimethylsulfoxide solvate, crystalline lenvatinib ethane sulfonate Form a, crystalline lenvatinib ethanesulfonate Form β, and crystalline lenvatinib ethanesulfonate dimethylsulfoxide solvate.
There is a need for the development of a salt of lenvatinib and its polymorph having improved solubility, stability, bioavailability, and storage and handling stability, and less susceptibility to degradation.
Summary of the Invention
The present invention provides a compound of Formula 1
Formula 1
wherein HX is selected from the group consisting of acetic acid, L-proline, maleic acid, citric acid, salicylic acid, succinic acid, and L-pyroglutamic acid and processes for their preparation.
More specifically, the present invention provides lenvatinib acetate, lenvatinib L- proline, lenvatinib maleate, lenvatinib citrate, lenvatinib salicylate, lenvatinib succinate, lenvatinib L-pyroglutamate, their polymorphic forms, processes for their preparation, and pharmaceutical compositions thereof. The present invention further relates to the use of these salts of lenvatinib for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
Brief Description of the Figures
Figure 1 depicts an X-Ray Powder Diffraction (XRPD) pattern of crystalline lenvatinib acetate prepared as per Example 1.
Figure 2 depicts a Differential Scanning Calorimetry (DSC) thermogram of crystalline lenvatinib acetate prepared as per Example 1.
Figure 3 depicts the Fourier-Transform Infrared (ΡΉΡ) spectrum of crystalline lenvatinib acetate prepared as per Example 1.
Figure 4 depicts an XRPD pattern of crystalline lenvatinib L-proline prepared as per Example 2.
Figure 5 depicts a DSC thermogram of crystalline lenvatinib L-proline prepared as per Example 2.
Figure 6 depicts the FTIR spectrum of crystalline lenvatinib L-proline prepared as per Example 2.
Figure 7 depicts an XRPD pattern of crystalline lenvatinib maleate prepared as per Example 3.
Figure 8 depicts a DSC thermogram of crystalline lenvatinib maleate prepared as per Example 3.
Figure 9 depicts the FTIR spectrum of crystalline lenvatinib maleate prepared as per Example 3.
Figure 10 depicts an XRPD pattern of crystalline lenvatinib citrate prepared as per
Example 4.
Figure 1 1 depicts a DSC thermogram of crystalline lenvatinib citrate prepared as per Example 4.
Figure 12 depicts the FTIR spectrum of crystalline lenvatinib citrate prepared as per Example 4.
Figure 13 depicts an XRPD pattern of crystalline lenvatinib salicylate prepared as per Example 5.
Figure 14 depicts a DSC thermogram of crystalline lenvatinib salicylate prepared as per Example 5.
Figure 15 depicts the FTIR spectrum of crystalline lenvatinib salicylate prepared as per Example 5.
Figure 16 depicts an XRPD pattern of crystalline lenvatinib succinate prepared as per Example 6.
Figure 17 depicts a DSC thermogram of crystalline lenvatinib succinate prepared as per Example 6.
Figure 18 depicts the FTIR spectrum of crystalline lenvatinib succinate prepared as per Example 6.
Figure 19 depicts an XRPD pattern of crystalline lenvatinib L-pyroglutamate prepared as per Example 7.
Figure 20 depicts a DSC thermogram of crystalline lenvatinib L-pyroglutamate prepared as per Example 7.
Figure 21 depicts the FTIR spectrum of crystalline lenvatinib L-pyroglutamate prepared as per Example 7.
Detailed Description of the Invention
The term "about," as used herein, refers to any value which lies within the range defined by a number up to ±10% of the value.
The term "solvent," includes single solvents or solvent mixtures, such as water, esters, alkanols, halogenated hydrocarbons, ketones, ethers, polar aprotic solvents, or mixtures thereof.
Examples of esters include ethyl acetate, n-propyl acetate, isopropyl acetate, and n-butyl acetate. Examples of alkanols include those primary, secondary, and tertiary alcohols having from one to six carbon atoms. Examples of alkanols include methanol, ethanol, n-propanol, isopropanol, butanol, 2-methoxyethanol, and 2-ethoxyethanol. Examples of halogenated hydrocarbons include dichloromethane, chloroform, and 1,2- dichloroethane. Examples of ketones include acetone and methyl ethyl ketone. Examples of ethers include diethyl ether and tetrahydrofuran. Examples of polar aprotic solvents include N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile, and N-methylpyrrolidone.
A first aspect of the present invention provides a compound of Formula 1
Formula 1
wherein HX is selected from the group consisting of acetic acid, L-proline, maleic acid, citric acid, salicylic acid, succinic acid, and L-pyroglutamic acid.
The compound of Formula 1 of the present invention may be in crystalline form or in an amorphous form.
In one embodiment of this aspect, the present invention provides crystalline lenvatinib acetate. Crystalline lenvatinib acetate is characterized by an XRPD pattern having interplanar spacing (d) values at about 21.9, 7.2, 5.4, 4.1, and 3.3 (A). Crystalline lenvatinib acetate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 8.6, 6.4, 4.7, 4.6, 3.8, 3.2, and 3.0 (A).
Crystalline lenvatinib acetate is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 4.0, 12.3, 16.4, 21.6, 26.6 ± 0.2°. Crystalline lenvatinib acetate is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 10.3, 13.9, 18.9, 19.4, 23.4, 28.0, and 29.4 ± 0.2°.
Table 1 provides the interplanar spacing (d) values (A), the corresponding peak values (2Θ), and the relative intensity of crystalline lenvatinib acetate.
Table 1
Interplanar spacing Peak values Relative
(d) values (A) (±0.2° 2Θ) Intensity (%)
21.9 4.0 81.2
10.8 8.2 4.1
8.6 10.3 55.1
7.2 12.3 89.0
6.4 13.9 21.1
5.4 16.4 92.8
5.1 17.2 12.3
4.8 18.4 3.4
4.7 18.9 46.6
4.6 19.4 17.1
4.5 19.9 9.5
4.3 20.8 14.8
4.2 21.1 8.2
4.1 21.6 67.8
4.0 22.3 4.5
3.8 23.4 28.9
3.7 24.2 12.8
3.6 24.8 1.8
3.3 26.6 100.0
3.2 28.0 33.8
3.1 28.7 12.1
3.1 29.1 9.9
3.0 29.4 67.0
2.9 30.4 1.3
2.7 32.7 7.0
2.6 34.2 7.2
Crystalline lenvatinib acetate is characterized by X-ray powder diffraction (XRPD) pattern substantially as depicted in Figure 1.
Crystalline lenvatinib acetate is characterized by a Differential Scanning Calorimetry (DSC) thermogram having an endothermic peak value at about 226.58°C.
Crystalline lenvatinib acetate is characterized by a Differential Scanning
Calorimetry (DSC) thermogram as depicted in Figure 2.
Crystalline lenvatinib acetate is characterized by a Fourier-Transform Infrared (FTIR) spectrum as depicted in Figure 3.
In another embodiment of this aspect, the present invention provides crystalline lenvatinib L-proline. Crystalline lenvatinib L-proline is characterized by an XRPD pattern having interplanar spacing (d) values at about 21.9, 7.2, 5.4, 4.7, and 3.4 (A). Crystalline lenvatinib L-proline is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 8.6, 4.3, 4.1, 3.8, 3.2, 3.1, and 3.0 (A).
Crystalline lenvatinib L-proline is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 4.0, 12.3, 16.4, 18.9, and 26.6± 0.2°. Crystalline lenvatinib L-proline is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 10.2, 20.8, 21.6, 23.3, 28.0, 29.0, and 29.3± 0.2°.
Table 2 provides the interplanar spacing (d) values (A), the corresponding peak values (2Θ), and the relative intensity of crystalline lenvatinib L-proline.
Table 2
Crystalline lenvatinib L-proline is characterized by an XRPD pattern as depicted in Figure 4.
Crystalline lenvatinib L-proline is characterized by a DSC thermogram having an endothermic peak value at about 225.27°C.
Crystalline lenvatinib L-proline is characterized by a DSC thermogram as depicted in Figure 5.
Crystalline lenvatinib L-proline is characterized by a FTIR spectrum as depicted in Figure 6.
In another embodiment of this aspect, the present invention provides crystalline lenvatinib maleate. Crystalline lenvatinib maleate is characterized by an XRPD pattern having interplanar spacing (d) values at about 19.7, 9.8, 6.0, 3.9, and 3.4 (A). Crystalline lenvatinib maleate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 13.9, 9.2, 8.5, 6.3, 4.1, 3.2, and 3.0 (A).
Crystalline lenvatinib maleate is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 4.5, 9.0, 14.6, 22.5, and 26.5± 0.2°. Crystalline lenvatinib maleate is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 6.4, 9.6, 10.4, 14.1, 21.7, 27.9, 29.4± 0.2°.
Table 3 provides the interplanar spacing (d) values (A), the corresponding peak values (2Θ), and the relative intensity of crystalline lenvatinib maleate.
Table 3
Crystalline lenvatinib maleate is characterized by an XRPD pattern as depicted in Figure 7.
Crystalline lenvatinib maleate is characterized by a DSC thermogram having endothermic peaks value at about 73.26°C and 172.69°C.
Crystalline lenvatinib maleate is characterized by a DSC thermogram as depicted in Figure 8.
Crystalline lenvatinib maleate is characterized by a FTIR spectrum as depicted in Figure 9.
In another embodiment of this aspect, the present invention provides crystalline lenvatinib citrate. Crystalline lenvatinib citrate is characterized by an XRPD pattern having interplanar spacing (d) values at about 7.2, 4.7, 4.1, 3.4, and 3.1 (A). Crystalline lenvatinib citrate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 21.9, 8.6, 5.4, 4.3, 3.8, and 3.2 (A).
Crystalline lenvatinib citrate is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 12.3, 18.9, 21.6, 26.5, and 29.3 ± 0.2°. Crystalline lenvatinib citrate is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 4.0, 10.2, 16.4, 20.8, 23.3, and 27.9± 0.2°.
Table 4 provides the interplanar spacing (d) values (A), the corresponding peak values (2Θ), and the relative intensity of crystalline lenvatinib citrate.
Table 4
Crystalline lenvatinib citrate is characterized by an XRPD pattern substantially as depicted in Figure 10.
Crystalline lenvatinib citrate is characterized by a DSC thermogram having an endothermic peak value at about 227.72°C and an exothermic peak value at about 270.04°C.
Crystalline lenvatinib citrate is characterized by a DSC thermogram as depicted in Figure 11.
Crystalline lenvatinib citrate is characterized by a FTIR spectrum as depicted in Figure 12.
In another embodiment of this aspect, the present invention provides crystalline lenvatinib salicylate. Crystalline lenvatinib salicylate is characterized by an XRPD pattern having interplanar spacing (d) values at about 25.3, 8.3, and 5.0 (A). Crystalline lenvatinib salicylate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about at 21.9, 7.2, 7.0, 6.0, 5.4, 4.1, 4.0, 3.5, and 3.3 (A).
Crystalline lenvatinib salicylate is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 3.5, 10.6, and 17.8 ± 0.2°. Crystalline lenvatinib salicylate is further characterized by an XRPD pattern having additional characteristic peak values (20) at 4.O, 12.3, 12.6, 14.8, 16.4, 21.4, 22.2, 25.2, and 26.8 ± 0.2°.
Table 5 provides the d-spacing values (A), the corresponding 2Θ values, and the relative intensity of crystalline lenvatinib salicylate.
Table 5
Interplanar spacing Peak values Relative
(d) values (A) (±0.2° 2Θ) Intensity (%)
25.3 3.5 54.0
21.9 4.0 5.0
12.6 7.0 3.3
10.8 8.2 1.1
8.3 10.6 100.0
7.2 12.3 8.7
7.0 12.6 5.2
6.5 13.6 0.9
6.2 14.2 1.2
6.0 14.8 6.7
5.5 16.0 2.5
5.4 16.4 5.0
5.0 17.8 69.3
4.8 18.3 0.6
4.7 19.0 1.3
4.5 19.54 2.9
4.3 20.8 0.6
4.1 21.4 9.1
4.1 21.5 0.8
4.0 22.2 8.6
3.8 23.7 0.9
3.6 24.7 3.3
3.5 25.2 5.7
3.4 26.1 2.6
3.3 26.8 7.8
3.3 27.2 1.8
3.2 27.6 1.8
3.1 28.1 1.5
3.1 28.6 4.2
3.1 29.0 2.1
3.0 29.4 1.3
3.0 30.2 1.0
2.8 32.0 1.6
2.7 33.5 0.9
2.6 34.2 0.9
Crystalline lenvatinib salicylate is characterized by an XRPD pattern substantially as depicted in Figure 13.
Crystalline lenvatinib salicylate is characterized by a DSC thermogram having an endothermic peak value at about 214.47°C.
Crystalline lenvatinib salicylate is characterized by a DSC thermogram as depicted in Figure 14.
Crystalline lenvatinib salicylate is characterized by a FTIR spectrum as depicted in Figure 15.
In another embodiment of this aspect, the present invention provides crystalline lenvatinib succinate. Crystalline lenvatinib succinate is characterized by an XRPD pattern having interplanar spacing (d) values at about 21.7, 8.6, 7.2, 5.4, 4.1, and 3.3 (A). Crystalline lenvatinib succinate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 8.6, 4.7, 4.3, 3.8, 3.2, 3.1, and 3.0 (A).
Crystalline lenvatinib succinate is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 4.1, 10.3, 12.3, 16.4, 21.6, and 26.6±0.2°. Crystalline lenvatinib succinate is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 10.3, 18.9, 20.8, 23.3, 28.0, 29.0, and 29.4± 0.2°.
Table 6 provides the interplanar spacing (d) values (A), the corresponding peak values (2Θ), and the relative intensity of crystalline lenvatinib succinate.
Table 6
Crystalline lenvatinib succinate is characterized by an XRPD pattern substantially as depicted in Figure 16.
Crystalline lenvatinib succinate is characterized by a DSC thermogram having an endothermic peak value at about 226.17°C and an exothermic peak value at about 268.97°C.
Crystalline lenvatinib succinate is characterized by a DSC thermogram as depicted in Figure 17.
Crystalline Form of lenvatinib succinate is characterized by a FTIR spectrum as depicted in Figure 18.
In another embodiment of this aspect, the present invention provides crystalline lenvatinib L-pyroglutamate. Crystalline lenvatinib L-pyroglutamate is characterized by an
XRPD pattern having interplanar spacing (d) values at about 21.6, 7.2, 5.4, 4.1, and 3.3 (A). Crystalline lenvatinib L-pyroglutamate is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about at 8.6, 4.7, 4.0, 3.8, 3.2, 3.1, 3.1, and 3.0 (A).
Crystalline lenvatinib L-pyroglutamate is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 4.1, 12.3, 16.5, 21.6, and 26.6± 0.2°. Crystalline lenvatinib L-pyroglutamate is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 10.3, 19.0, 21.9, 23.3, 28.0, 28.6, 29.0, and 29.3 ± 0.2°.
Table 7 provides the interplanar spacing (d) values (A), the corresponding peak values (2Θ), and the relative intensity of crystalline lenvatinib L-pyroglutamate.
Table 7
Interplanar spacing Peak values Relative Intensity
(d) values (A) (±0.2° 2Θ) (%)
21.6 4.1 54.2
18.4 4.8 1.0
10.7 8.2 3.5
9.1 9.7 7.0
8.6 10.3 36.8
7.2 12.3 59.5
6.4 13.9 13.2
6.0 14.7 2.5
5.4 16.5 63.1
5.1 17.3 11.9
4.7 19.0 42.8
4.5 19.6 15.0
4.5 19.9 5.2
4.3 20.8 11.0
4.2 21.2 12.9
4.1 21.6 54.4
4.0 21.9 32.2
3.9 22.9 9.0
3.8 23.3 32.7
3.7 24.2 7.4
3.3 26.6 100.0
3.2 28.0 23.8
3.1 28.6 26.7
3.1 29.0 23.8
3.0 29.3 52.4
2.9 30.4 1.30
2.9 30.9 2.2
2.8 31.4 1.3
2.7 32.7 8.3
Crystalline lenvatinib L-pyroglutamate is characterized by an XRPD pattern substantially as depicted in Figure 19.
Crystalline lenvatinib L-pyroglutamate is characterized by a DSC thermogram having endothermic peak values at about 151.77°C and 199.85°C.
Crystalline lenvatinib L-pyroglutamate is characterized by a DSC thermogram as depicted in Figure 20.
Crystalline lenvatinib L-pyroglutamate is characterized by a FTIR spectrum as depicted in Figure 21.
A second aspect of the present invention provides a process for the preparation of a compound of Formula 1
Formula 1
comprising the steps of:
a) treating lenvatinib free base with HX in a solvent; and
b) isolating the compound of Formula 1;
wherein HX is selected from the group consisting of acetic acid, L-proline, maleic acid, citric acid, salicylic acid, succinic acid, and L-pyroglutamic acid.
Lenvatinib free base used as the starting material may be prepared by any methods known in the art including those described in, for example, U.S. Patent Nos. 7,253,286, and 7,683,172.
Lenvatinib free base prepared by any methods known in the art may be isolated or directly treated with HX.
Lenvatinib free base prepared by any methods known in the art may be optionally purified prior to treatment with HX to remove foreign particulate matter. Alternatively, it may be treated with activated charcoal in a suitable solvent to remove coloring and other related impurities.
The treatment of lenvatinib free base with HX includes adding, slurrying, dissolving, stirring, or a combination thereof in the presence of a suitable solvent at a temperature of about 25 °C to reflux temperature for a time period sufficient to complete the reaction.
The molar ratio of lenvatinib free base to HX may be about 1 :0.5 to about 1 :2, which may be preferably 1 : 1.
After completion of the reaction, compound of Formula 1 can be isolated by cooling, extraction, washing, crystallization, precipitation, filtration, filtration under vacuum, decantation, centrifugation, drying, or combinations thereof.
The compound of Formula 1 obtained by the process above is crystalline or amorphous.
In one embodiment of this aspect, lenvatinib is treated with acetic acid at a temperature of about 25°C to 30°C in methanol to isolate crystalline lenvatinib acetate.
In another embodiment of this aspect, lenvatinib free base is treated with L-proline at a temperature of about 25°C to 75°C in ethanol to isolate crystalline lenvatinib L- proline.
In another embodiment of this aspect, lenvatinib free base is treated with maleic acid at a temperature of about 25 °C to 75 °C in ethanol to isolate crystalline lenvatinib maleate.
In another embodiment of this aspect, lenvatinib free base is treated with citric acid at a temperature of about 25 °C to 65 °C in methanol to isolate crystalline lenvatinib citrate.
In another embodiment of this aspect, lenvatinib free base is treated with salicylic acid at a temperature of about 25 °C to 65 °C in methanol to isolate crystalline lenvatinib salicylate.
In another embodiment of this aspect, lenvatinib free base is treated with L- pyroglutamic acid at a temperature of about 25°C to 70°C in ethanol to isolate crystalline lenvatinib L-pyroglutamate.
A third aspect of the present invention provides the use of compound of Formula 1 for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
In one embodiment of this aspect, the compound of Formula 1 can be used for the preparation of lenvatinib free base by contacting with a base. The base may be selected from the group consisting of hydroxides, carbonates, and bicarbonates of alkali and alkaline earth metals, ammonia, alkyl amines, hydrazine, and the like. Examples of hydroxides, carbonates, and bicarbonates of alkali and alkaline earth metals include lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, and potassium bicarbonate. Examples of alkyl amines include diethylamine, triethylamine, and methyldiethylamine. Lenvatinib free base thus obtained may be converted to salts, solvates, or polymorphs thereof by any of the methods known in the art. Preferably, lenvatinib free base obtained may be converted to the mesylate salt including those described in, for example, U.S. Patent Nos. 7,612,208
A fourth aspect of the present invention provides a pharmaceutical composition comprising a compound of Formula 1 and a pharmaceutically acceptable carrier.
While the present invention has been described in terms of its specific aspects, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be within the scope of the present invention.
Methods:
The details of the instrument used are as follows:
DSC: 821e Mettler Toledo®
FTIR: Perkin Elmer® Spectrum One FT-IR Spectrometer
XRPD of samples were determined using a Rigaku® instrument; Model: MiniFlex600; Detector: D/teX Ultra.
The following examples are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way.
EXAMPLES
Example 1 : Preparation of Lenvatinib Acetate
Acetic acid (0.14 g) was added to a mixture of lenvatinib free base (1 g) and methanol (15 mL) at 25 °C to 30°C and stirred for 24 hours. The solid obtained was filtered and then washed with methanol (2x5 mL). The solid was dried under reduced pressure at 45°C to 50°C for 15 hours to obtain the title compound.
Yield: 0.6 g
Example 2: Preparation of Lenvatinib L-proline:
L-Proline (0.134 g) was added to a mixture of lenvatinib free base (0.5 g) and ethanol (10 mL) at 70°C to 75°C and stirred for 25 minutes. The reaction mixture was cooled to 25 °C to 30°C and then stirred for 18 hours. The solid obtained was filtered and then washed with ethanol (2x5mL). The solid was dried under reduced pressure at 50°C to 55 °C for 18 hours to obtain the title compound.
Yield: 0.45 g
Example 3: Preparation of Lenvatinib Maleate:
Maleic acid (0.136 g) was added to a mixture of lenvatinib free base (0.5 g) and ethanol (10 mL) at 70°C to 75°C. The reaction mixture was cooled to 25°C to 30°C and then stirred for 18 hours. The solid obtained was filtered and then washed with ethanol (2x5mL). The solid was dried under reduced pressure at 50°C to 55°C for 18 hours to obtain the title compound.
Yield: 0.48 g
Example 4: Preparation of Lenvatinib Citrate:
Citric acid (0.247 g) was added to a mixture of lenvatinib free base (0.5 g) and methanol (10 mL) at 64°C to 65°C and stirred for 1 hour. The reaction mixture was cooled to 25°C to 30°C and stirred for 15 hours. The solid obtained was filtered and then washed with methanol (2x5mL). The solid was dried under reduced pressure at 50°C to 55°C for 18 hours to obtain the title compound.
Yield: 0.67 g
Example 5: Preparation of Lenvatinib Salicylate:
Salicylic acid (0.18 g) was added to a mixture of lenvatinib free base (0.5 g) and methanol (10 mL) at 64°C to 65°C and stirred for 1 hour. The reaction mixture was cooled to 25 °C to 30°C and then stirred for 15 hours. The solid obtained was filtered and then washed with methanol (2x5mL). The solid was dried under reduced pressure at 50°C to 55°C for 18 hours to obtain the title compound.
Yield: 0.72 g
Example 6: Preparation of Lenvatinib Succinate:
Succinic acid (0.15 g) was added to a mixture of lenvatinib free base (0.5 g) and ethanol (10 mL) at 70°C and stirred for 1 hour at 65-70°C. The reaction mixture was cooled to 25 °C to 30°C and then stirred for 15 hours at 25 °C to 30°C. The solid obtained was filtered and then washed with ethanol (5mL). The solid was dried under reduced pressure at 50°C to 55°C for 18 hours to obtain the title compound.
Yield: 0.68 g
Example 7: Preparation of Lenvatinib L-pyroglutamate:
L-pyroglutamic acid (0.18 g) was added to a mixture of lenvatinib free base (0.5 g) and ethyl acetate (20 mL) at 70°C and stirred for 1 hour at 68-70°C. The reaction mixture was cooled to 25 °C to 30°C and then stirred for 15 hours. The solid obtained was filtered and then washed with ethyl acetate (2x5 mL). The solid was dried under reduced pressure at 50°C to 55°C for 18 hours to obtain the title compound.
Yield: 0.71 g
Example 8: A General Method for Preparation of Lenvatinib Free Base
A suspension of compound of Formula 1 in water (about 10 times) is cooled to 10°C and then the pH is adjusted to 8-9 using aqueous ammonia solution. The reaction mixture is stirred for 30 minutes, the material is filtered, and dried to obtain the title compound.
Claims
1. A compound of Formula 1
Formula 1
wherein HX is selected from the group consisting of acetic acid, L-proline, maleic acid, citric acid, salicylic acid, succinic acid, and L-pyroglutamic acid.
2. The compound of Formula 1 according to claim 1, which is in a crystalline form or in an amorphous form.
3. Crystalline lenvatinib acetate.
4. The crystalline lenvatinib acetate according to claim 3, wherein the crystalline form is characterized by an XRPD pattern having interplanar spacing (d) values at about 21.9, 7.2, 5.4, 4.1, and 3.3 (A).
5. The crystalline lenvatinib acetate according to claim 4, wherein the crystalline form is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 8.6, 6.4, 4.7, 4.6, 3.8, 3.2, and 3.0 (A).
6. The crystalline lenvatinib acetate according to claim 3, wherein the crystalline form is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 4.0, 12.3, 16.4, 21.6, 26.6 ± 0.2°.
7. The crystalline lenvatinib acetate according to claim 6, wherein the crystalline form is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 10.3, 13.9, 18.9, 19.4, 23.4, 28.0, and 29.4 ± 0.2°.
8. The crystalline lenvatinib acetate according to claim 3, wherein the crystalline form is characterized by X-ray powder diffraction (XRPD) pattern substantially as depicted in Figure 1.
9. The crystalline lenvatinib acetate according to claim 3, wherein the crystalline form is characterized by a Differential Scanning Calorimetry (DSC) thermogram having an endothermic peak value at about 226.58°C.
10. The crystalline lenvatinib acetate according to claim 3, wherein the crystalline form is characterized by a Differential Scanning Calorimetry (DSC) thermogram as depicted in Figure 2.
11. The crystalline lenvatinib acetate according to claim 3, wherein the crystalline form is characterized by a Fourier-Transform Infrared (FTIR) spectrum as depicted in Figure 3.
12. Crystalline lenvatinib L-Proline.
13. The crystalline lenvatinib L-proline according to claim 12, wherein the crystalline form is characterized by an XRPD pattern having interplanar spacing (d) values at about 21.9, 7.2, 5.4, 4.7, and 3.4 (A).
14. The crystalline lenvatinib L-proline according to claim 13, wherein the crystalline form is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 8.6, 4.3, 4.1, 3.8, 3.2, 3.1, and 3.0 (A).
15. The crystalline lenvatinib L-proline according to claim 12, wherein the crystalline form is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 4.0, 12.3, 16.4, 18.9, and 26.6± 0.2°.
16. The crystalline lenvatinib L-proline according to claim 15, wherein the crystalline form is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 10.2, 20.8, 21.6, 23.3, 28.0, 29.0, and 29.3± 0.2°.
17. The crystalline lenvatinib L-proline according to claim 12, wherein the crystalline form is characterized by an XRPD pattern as depicted in Figure 4.
18. The crystalline lenvatinib L-proline according to claim 12, wherein the crystalline form is characterized by a DSC thermogram having an endothermic peak value at about 225.27°C.
19. The crystalline lenvatinib L-proline according to claim 12, wherein the crystalline form is characterized by a DSC thermogram as depicted in Figure 5.
20. The crystalline lenvatinib L-proline according to claim 12, wherein the crystalline form is characterized by a FTIR spectrum as depicted in Figure 6.
21. Crystalline lenvatinib maleate.
22. The crystalline lenvatinib maleate according to claim 21, wherein the crystalline form is characterized by an XRPD pattern having interplanar spacing (d) values at about 19.7, 9.8, 6.0, 3.9, and 3.4 (A).
23. The crystalline lenvatinib maleate according to claim 22, wherein the crystalline form is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 13.9, 9.2, 8.5, 6.3, 4.1, 3.2, and 3.0 (A).
24. The crystalline lenvatinib maleate according to claim 21, wherein the crystalline form is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 4.5, 9.0, 14.6, 22.5, and 26.5± 0.2°.
25. The crystalline lenvatinib maleate according to claim 24, wherein the crystalline form is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 6.4, 9.6, 10.4, 14.1, 21.7, 27.9, and 29.4± 0.2°.
26. The crystalline lenvatinib maleate according to claim 21, wherein the crystalline form is characterized by an XRPD pattern as depicted in Figure 7.
27. The crystalline lenvatinib maleate according to claim 21, wherein the crystalline form is characterized by a DSC thermogram having endothermic peaks value at about 73.26°C and 172.69°C.
28. The crystalline lenvatinib maleate according to claim 21, wherein the crystalline form is characterized by a DSC thermogram as depicted in Figure 8.
29. The crystalline lenvatinib maleate according to claim 21, wherein the crystalline form is characterized by a FTIR spectrum as depicted in Figure 9.
30. Crystalline lenvatinib citrate.
31. The crystalline lenvatinib citrate according to claim 30, wherein the crystalline form is characterized by an XRPD pattern having interplanar spacing (d) values at about 7.2, 4.7, 4.1, 3.4, and 3.1 (A).
32. The crystalline lenvatinib citrate according to claim 31, wherein the crystalline form is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 21.9, 8.6, 5.4, 4.3, 3.8, and 3.2 (A).
33. The crystalline lenvatinib citrate according to claim 30, wherein the crystalline form is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 12.3, 18.9, 21.6, 26.5, and 29.3 ± 0.2°.
34. The crystalline lenvatinib citrate according to claim 33, wherein the crystalline form is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 4.0, 10.2, 16.4, 20.8, 23.3, and 27.9± 0.2°.
35. The crystalline lenvatinib citrate according to claim 30, wherein the crystalline form is characterized by an XRPD pattern substantially as depicted in Figure 10.
36. The crystalline lenvatinib citrate according to claim 30, wherein the crystalline form is characterized by a DSC thermogram having an endothermic peak value at about 227.72°C and an exothermic peak value at about 270.04°C.
37. The crystalline lenvatinib citrate according to claim 30, wherein the crystalline form is characterized by a DSC thermogram as depicted in Figure 11.
38. The crystalline lenvatinib citrate according to claim 30, wherein the crystalline form is characterized by a FTIR spectrum as depicted in Figure 12.
39. Crystalline lenvatinib salicylate.
40. The crystalline lenvatinib salicylate according to claim 39, wherein the crystalline form is characterized by an XRPD pattern having interplanar spacing (d) values at about 25.3, 8.3, and 5.0 (A).
41. The crystalline lenvatinib salicylate according to claim 40, wherein the crystalline form is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about at 21.9, 7.2, 7.0, 6.0, 5.4, 4.1, 4.0, 3.5, and 3.3 (A).
42. The crystalline lenvatinib salicylate according to claim 39, wherein the crystalline form is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 3.5, 10.6, and 17.8 ± 0.2°.
43. The crystalline lenvatinib salicylate according to claim 42, wherein the crystalline form is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 4.0, 12.3, 12.6, 14.8, 16.4, 21.4, 22.2, 25.2, and 26.8 ± 0.2°.
44. The crystalline lenvatinib salicylate according to claim 39, wherein the crystalline form is characterized by an XRPD pattern substantially as depicted in Figure 13.
45. The crystalline lenvatinib salicylate according to claim 39, wherein the crystalline form is characterized by a DSC thermogram having an endothermic peak value at about 214.47°C.
46. The crystalline lenvatinib salicylate according to claim 39, wherein the crystalline form is characterized by a DSC thermogram as depicted in Figure 14.
47. The crystalline lenvatinib salicylate according to claim 39, wherein the crystalline form is characterized by a FTIR spectrum as depicted in Figure 15.
48. Crystalline lenvatinib succinate.
49. The crystalline lenvatinib succinate according to claim 48, wherein the crystalline form is characterized by an XRPD pattern having interplanar spacing (d) values at about 21.7, 8.6, 7.2, 5.4, 4.1, and 3.3 (A).
50. The crystalline lenvatinib succinate according to claim 49, wherein the crystalline form is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about 8.6, 4.7, 4.3, 3.8, 3.2, 3.1, and 3.0 (A).
51. The crystalline lenvatinib succinate according to claim 48, wherein the crystalline form is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 4.1, 10.3, 12.3, 16.4, 21.6, and 26.6±0.2°.
52. The crystalline lenvatinib succinate according to claim 51, wherein the crystalline form is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 10.3, 18.9, 20.8, 23.3, 28.0, 29.0, and 29.4± 0.2°.
53. The crystalline lenvatinib succinate according to claim 48, wherein the crystalline form is characterized by an XRPD pattern substantially as depicted in Figure 16.
54. The crystalline lenvatinib succinate according to claim 48, wherein the crystalline form is characterized by a DSC thermogram having an endothermic peak value at about 226.17°C and an exothermic peak value at about 268.97°C.
55. The crystalline lenvatinib succinate according to claim 48, wherein the crystalline form is characterized by a DSC thermogram as depicted in Figure 17.
56. The crystalline Form of lenvatinib succinate according to claim 48, wherein the crystalline form is characterized by a FTIR spectrum as depicted in Figure 18.
57. Crystalline lenvatinib L-pyroglutamate.
58. The crystalline lenvatinib L-pyroglutamate according to claim 57, wherein the crystalline form is characterized by an XRPD pattern having interplanar spacing (d) values at about 21.6, 7.2, 5.4, 4.1, and 3.3 (A).
59. The crystalline lenvatinib L-pyroglutamate according to claim 58, wherein the crystalline form is further characterized by an XRPD pattern having additional interplanar spacing (d) values at about at 8.6, 4.7, 4.0, 3.8, 3.2, 3.1, 3.1, and 3.0 (A).
60. The crystalline lenvatinib L-pyroglutamate according to claim 57, wherein the crystalline form is characterized by an XRPD pattern having characteristic peak values (2Θ) at about 4.1, 12.3, 16.5, 21.6, and 26.6± 0.2°.
61. The crystalline lenvatinib L-pyroglutamate according to claim 60, wherein the crystalline form is further characterized by an XRPD pattern having additional characteristic peak values (2Θ) at 10.3, 19.0, 21.9, 23.3, 28.0, 28.6, 29.0, and 29.3 ± 0.2°.
62. The crystalline lenvatinib L-pyroglutamate according to claim 57, wherein the crystalline form is characterized by an XRPD pattern substantially as depicted in Figure 19.
63. The crystalline lenvatinib L-pyroglutamate according to claim 57, wherein the crystalline form is characterized by a DSC thermogram having endothermic peak values at about 151.77°C and 199.85°C.
64. The crystalline lenvatinib L-pyroglutamate according to claim 57, wherein the crystalline form is characterized by a DSC thermogram as depicted in Figure 20.
65. The crystalline lenvatinib L-pyroglutamate according to claim 57, wherein the crystalline form is characterized by a FTIR spectrum as depicted in Figure 21.
66. A process for the preparation of a compound of Formula 1
Formula 1
comprising the steps of:
a) treating lenvatinib free base with HX in a solvent; and
b) isolating the compound of Formula 1 ;
wherein HX is selected from the group consisting of acetic acid, L-proline, maleic acid, citric acid, salicylic acid, succinic acid, and L-pyroglutamic acid.
67. The process according to claim 66, wherein the treatment of lenvatinib free base with HX comprises adding, slurrying, dissolving, stirring, or a combination thereof, of lenvatinib free base with HX.
68. The process according to claim 66, wherein in the step a) the molar ratio of lenvatinib free base to HX is about 1 : 0.5 to about 1 :2.
69. The process according to claim 66, wherein the compound of Formula 1 is isolated by a method involving one or more of cooling, extraction, washing, crystallization, precipitation, filtration, filtration under vacuum, decantation, centrifugation, drying, or combinations thereof.
70. The process according to claim 66, wherein the compound of Formula 1 obtained is crystalline or amorphous.
71. The process according to claim 66, wherein lenvatinib free base is treated with acetic acid at a temperature of about 25°C to 30°C in methanol.
72. The process according to claim 66, wherein lenvatinib free base is treated with L- proline at a temperature of about 25°C to 75°C in ethanol.
73. The process according to claim 66, wherein lenvatinib free base is treated with maleic acid at a temperature of about 25°C to 75°C in ethanol.
74. The process according to claim 66, wherein lenvatinib free base is treated with citric acid at a temperature of about 25 °C to 65 °C in methanol.
75. The process according to claim 66, wherein lenvatinib free base is treated with salicylic acid at a temperature of about 25 °C to 65 °C in methanol.
76. The process according to claim 66, wherein lenvatinib free base is treated with L- pyroglutamic acid at a temperature of about 25 °C to 70°C in ethanol.
77. Use of the compound of Formula 1 according to claim 1, for the preparation of lenvatinib free base or other salts, solvates, or polymorphs thereof.
78. A pharmaceutical composition comprising the compound of Formula 1 according to claim 1, and a pharmaceutically acceptable carrier.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201611021561 | 2016-06-23 | ||
IN201611021561 | 2016-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017221215A1 true WO2017221215A1 (en) | 2017-12-28 |
Family
ID=60784356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2017/053777 WO2017221215A1 (en) | 2016-06-23 | 2017-06-23 | Salts of lenvatinib |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017221215A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070037849A1 (en) * | 2003-11-11 | 2007-02-15 | Toshihiko Naito | Urea derivative and process for producing the same |
US20070078159A1 (en) * | 2003-12-25 | 2007-04-05 | Tomohiro Matsushima | A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amin ophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
US20100324067A1 (en) * | 2007-11-05 | 2010-12-23 | Gang Liu | Tetracyclic dipyrano-coumarin compounds with anti-hiv and anti-mycobacterium tuberculosis activities |
-
2017
- 2017-06-23 WO PCT/IB2017/053777 patent/WO2017221215A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070037849A1 (en) * | 2003-11-11 | 2007-02-15 | Toshihiko Naito | Urea derivative and process for producing the same |
US20070078159A1 (en) * | 2003-12-25 | 2007-04-05 | Tomohiro Matsushima | A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amin ophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
US20100324067A1 (en) * | 2007-11-05 | 2010-12-23 | Gang Liu | Tetracyclic dipyrano-coumarin compounds with anti-hiv and anti-mycobacterium tuberculosis activities |
Non-Patent Citations (1)
Title |
---|
OKAMOTO, K ET AL.: "Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization", ACS MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 1, pages 89 - 94, XP055445709 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3464285B1 (en) | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
WO2017016960A1 (en) | Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues | |
JP2014521726A5 (en) | ||
WO2017221214A1 (en) | Crystalline forms of salts of lenvatinib | |
EP2350055A1 (en) | Lenalidomide solvates and processes | |
WO2016178150A1 (en) | Novel polymorphs of axitinib | |
WO2013046229A1 (en) | Novel salts of alogliptin | |
WO2009109651A1 (en) | SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE | |
GB2550138A (en) | Process for preparing boscalid | |
US20130060030A1 (en) | Process for the preparation of highly pure crystalline imatinib base | |
EP2516412A1 (en) | Processes for the purification of lubiprostone | |
US10941116B2 (en) | Crystalline forms of mesaconine and preparation methods therefor | |
WO2017221215A1 (en) | Salts of lenvatinib | |
WO2017125504A1 (en) | Polymorphic forms of vortioxetine hydrobromide tert-butanolate | |
EP2243780A2 (en) | Process for the purification of paliperidone | |
JP2011505416A (en) | Process for the preparation of chemically and chirally pure solifenacin base and its salts | |
AU2016304852B2 (en) | Processes for preparing an FGFR inhibitor | |
US20130274478A1 (en) | Polymorphs of sorafenib acid addition salts | |
WO2015092624A1 (en) | Nilotinib mono-oxalate and its crystalline form | |
CN109516975B (en) | Medicinal salt of substituted pyrimidine PI3K inhibitor and preparation method thereof | |
AU2005277361A1 (en) | Process for the production of levorphanol and related compounds | |
EP1805168A1 (en) | Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | |
DK2164848T3 (en) | Polymorphic form of granisetronbase, to processes for obtaining them as well as the formulation containing the | |
EP2260037A2 (en) | A polymorphic form of a pyrazino [2,3-h] [3] benzazepine derivative | |
US11858928B2 (en) | Process for making palbociclib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17814876 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17814876 Country of ref document: EP Kind code of ref document: A1 |